
William Leonard Pickard x Jonathan Sporn: Ibogaine & Innovation
🎙️ JLS Podcast: Leaders in Biotech Interview with Jonathan Sporn, CEO of Gilgamesh Pharmaceuticals
🚀 Company Background Founded 4 years ago with a $5,000 investment, now raised $80M in Series A funding. NIH awarded $13M in non-dilutive grants. AbbVie investment: $60M upfront, $2B in milestone payments—largest psychedelic deal in history.
🧪 Origins of Gilgamesh Pharmaceuticals Jonathan Sporn (ex-Pfizer, Harvard MD) partnered with Columbia University chemists to design novel psychedelic-inspired molecules. Initial research began in a Columbia lab, licensing certain assets while ensuring company…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.